Waldemarus
- The US FDA has granted final approval to Lantheus Holdings’ (LNTH) Bravnesta (lutetium Lu 177 dotatate), a bioequivalent to Novartis’ (NVS) radiopharmaceutical to Lutathera.
- Bravnesta is used for the treatment of adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
- Bravnesta
